A randomized phase II trial of fulvestrant with or without Ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive HER2 negative breast cancer
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
